RT Journal Article
SR Electronic
T1 Role of a <em>CYP17</em> Promoter Polymorphism for Familial Prostate Cancer Risk in Germany
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1303
OP 1307
VO 25
IS 2B
A1 VESOVIC, ZORICA
A1 HERKOMMER, KATHLEEN
A1 VOGEL, WALTHER
A1 PAISS, THOMAS
A1 MAIER, CHRISTIANE
YR 2005
UL http://ar.iiarjournals.org/content/25/2B/1303.abstract
AB Background: A thymidine to cytosine transition (designated A2 variant) in the promoter region of CYP17 has previously been associated with a familial history of prostate cancer in North American families. The purpose of the present study was to determine whether this correlation could be replicated in a European population. Materials and Methods: Case-control comparisons were performed by modelling a dominant (A1/A2 + A2/A2 vs. A1/A1) and a recessive (A2/A2 vs. A1/A2 + A1/A1) effect of the promoter modification. Results: An insignificant overrepresentation of homozygous carriers of the A2 allele (recessive effect) was found in sporadic cases, as compared to controls. However, the A2 variant was not related to familial disease. Conclusion: Our results do not suggest a role of CYP17 as a high-risk susceptibility gene for familial prostate cancer, nor as a modifier for the disease risk in the European population. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved